multiple myeloma

Department

Implementing Clinical Pathways for Multiple Myeloma

04/12/2017

JCP Editors

Multiple myeloma represents a key area for clinical pathway development. In one survey of payers, 47.6% reported having pathways for multiple myeloma, with another 19.1% citing the cancer type as a high priority for...

...

04/12/2017

Journal of Clinical Pathways

Research in Review

Daratumumab Cost-Effective for Refractory Multiple Myeloma

04/10/2017

JCP Editors

Single agent daratumumab may serve as a more cost-effective treatment strategy than pomalidomide for patients with refractory multiple myeloma. ----- Related Content Daratumumab improves progression-free survival...

Single...

04/10/2017

Journal of Clinical Pathways

Research in Review

Meta-Analysis Reveals Optimal Combination Therapy for Multiple Myeloma

03/24/2017

JCP Editors

A triple-combination treatment strategy is the most effective therapy for patients with relapsed or refractory multiple myeloma, according to a meta-analysis published in the Journal of Clinical Oncology (published...

A...

03/24/2017

Journal of Clinical Pathways

Research in Review

Two-Drug Regimen Plus Bortezomib Improves Survival for Patients With Multiple Myeloma

12/29/2016

JCP Editors

The addition of bortezomib to lenalidomide with dexamethasone treatment significantly improves progression-free survival (PFS) and overall survival (OS) for patients with multiple myeloma, according to new clinical...

The...

12/29/2016

Journal of Clinical Pathways

Research in Review

In Head-to-Head Study, New Multiple Myeloma Drug Combination Shows Superiority

12/07/2015

JCP Editors

A phase 3 head-to-head trial comparing the effectiveness of Kyprolis (carfilzomib) in combination with dexamethasone has shown better outcomes in patients with multiple myeloma than the current standard of care,...

A...

12/07/2015

Journal of Clinical Pathways